Sökning: WFRF:(Feeney Amanda) >
Measuring what matt...
-
King, Madeleine T.Univ Sydney, Australia; Univ Sydney, Australia
(författare)
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
- Artikel/kapitelEngelska2018
Förlag, utgivningsår, omfång ...
-
2017-12-16
-
SPRINGER,2018
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-144892
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-144892URI
-
https://doi.org/10.1007/s11136-017-1729-8DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:137488064URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies|NHMRC [1063012, 570,893]; Target Ovarian Cancer [UCL-P001AL]; Cancer Research UK [C444/A15953]; UCL Cancer Trials Centre [C444/A15953]; Australian Government through Cancer Australia; NHMRC; Department of Health
-
Gynecologic Cancer Intergroup Symptom Benefit Study (GCIG-SBS) Stage 2 aimed to review, revise, and validate a patient-reported outcome measure (PROM), the Measure of Ovarian Symptoms and Treatment concerns (MOST), developed in GCIG-SBS Stage 1 (MOSTv1, 35 items), and document recurrent ovarian cancer (ROC) symptom burden and benefit. GCIG-SBS Stage 2 recruited patients with platinum-resistant/refractory ROC (PRR-ROC) or potentially platinum-sensitive ROC with aeamp;lt;yenamp;gt; 3 lines of prior chemotherapy (PPS-ROC aeamp;lt;yenamp;gt; 3). Patients completed MOSTv1, QLQ-C30, QLQ-OV28, and FACT-O/FOSI at baseline and before cycle 3 of chemotherapy (pre-C3), and global assessments of change (MOST-Change) pre-C3. Clinicians rated patients cancer-related symptoms, performance status, and adverse events. Convergent and divergent validity (Spearmans correlations), discriminative validity (effect sizes between groups classified by clinician-rated characteristics), and responsiveness (paired t tests in patients expected to experience clinically meaningful change) were assessed. Of 948 recruits, 903 completed PROMs at baseline and 685 pre-C3. Baseline symptom burden was substantial for PRR-ROC and PPS-ROC aeamp;lt;yenamp;gt; 3. MOSTv2 has 24 items and five multi-item scales: abdominal symptoms (MOST-Abdo), disease or treatment-related symptoms (MOST-DorT), chemotherapy-related symptoms (MOST-Chemo), psychological symptoms (MOST-Psych), and MOST-Well-being. Correlations confirmed concurrent and divergent validity. Discriminative validity was confirmed by effect sizes that conformed with a priori hypotheses. MOST-Abdo was responsive to improvements in abdominal symptoms and MOST-Chemo detected the adverse effects of chemotherapy. The MOSTv2 validly quantifies patient-reported symptom burden, adverse effects, and symptom benefit in ROC, and as such is fit-for-purpose for clinical trials of palliative chemotherapy in ROC. Further research is required to assess test-retest reliability.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Stockler, Martin R.ANZGOG, Australia
(författare)
-
OConnell, Rachel L.Univ Sydney, Australia
(författare)
-
Buizen, LukeUniv Sydney, Australia
(författare)
-
Joly, FlorenceCtr Francois Baclesse, France
(författare)
-
Lanceley, AnneUCL, England
(författare)
-
Hilpert, FelixKrankenhaus Jerusalem Hamburg, Germany
(författare)
-
Okamoto, AikouJikei Univ, Japan
(författare)
-
Aotani, ErikoKanagawa Acad Sci and Technol, Japan
(författare)
-
Bryce, JaneIRCCS, Italy
(författare)
-
Donnellan, PaulGalway Univ Hosp, Ireland
(författare)
-
Oza, AmitUniv Toronto, Canada
(författare)
-
Åvall-Lundqvist, Elisabeth,1957-Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Karolinska Inst, Sweden(Swepub:liu)eliav51
(författare)
-
Berek, Jonathan S.Stanford Comprehens Canc Inst, CA USA
(författare)
-
Sehouli, JalidAGO Study Grp, Germany,Univ Sydney, Australia
(författare)
-
Feeney, AmandaUCL, England
(författare)
-
Berton-Rigaud, DominiqueGINECO, France
(författare)
-
Costa, Daniel S. J.Univ Sydney, Australia
(författare)
-
Friedlander, Michael L.ANZGOG, Australia
(författare)
-
Univ Sydney, Australia; Univ Sydney, AustraliaANZGOG, Australia
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Quality of Life Research: SPRINGER27:1, s. 59-740962-93431573-2649
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
King, Madeleine ...
-
Stockler, Martin ...
-
OConnell, Rachel ...
-
Buizen, Luke
-
Joly, Florence
-
Lanceley, Anne
-
visa fler...
-
Hilpert, Felix
-
Okamoto, Aikou
-
Aotani, Eriko
-
Bryce, Jane
-
Donnellan, Paul
-
Oza, Amit
-
Åvall-Lundqvist, ...
-
Berek, Jonathan ...
-
Sehouli, Jalid
-
Feeney, Amanda
-
Berton-Rigaud, D ...
-
Costa, Daniel S. ...
-
Friedlander, Mic ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
- Artiklar i publikationen
-
Quality of Life ...
- Av lärosätet
-
Linköpings universitet
-
Karolinska Institutet